|Bid||30.54 x 2200|
|Ask||30.56 x 800|
|Day's range||30.34 - 31.39|
|52-week range||29.41 - 57.22|
|Beta (5Y monthly)||1.93|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||60.33|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs...
Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% and -42.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
If you own shares in Zogenix, Inc. (NASDAQ:ZGNX) then it's worth thinking about how it contributes to the volatility...
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Zogenix, Inc. resulting from allegations that Zogenix may have issued materially misleading business information to the investing public.
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Zogenix stock or options between February 6, 2019 and April 8, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/ZGNX. The case, Lake v. Zogenix, Inc. et al., No. 19-cv-01975 was filed on April 12, 2019, and has been assigned to Judge Richard Seeborg.
On a per-share basis, the Emeryville, California-based company said it had a loss of 83 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. On April 8, 2019, Zogenix announced that it received a refusal to file letter from the U.S. Food and Drug Administration (“FDA”) regarding Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed treatment for seizures associated with Dravet syndrome.
Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”). Investors suffering losses on their Zogenix investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to email@example.com.